Skip to main content

Table 10 Validity of the PROHIV-OLD instrument assessed by the known-groups method (n = 483)

From: Development and validation of the patient-reported outcome for older people living with HIV/AIDS in China (PROHIV-OLD)

Variable

N

Physical symptoms

 

Mental status

 

Illness perception

 

Family relationship

 

Treatment dimension

 
  

Mean (SD)

F

Mean (SD)

F

Mean (SD)

F

Mean (SD)

F

Mean (SD)

F

Gender

  

4.73*

 

4.50*

 

0.15

 

0.18

 

0.03

Male

400

64.44 (24.38)

 

66.18 (25.98)

 

54.08 (27.74)

 

59.33 (27.10)

 

62.41 (22.73)

 

Female

83

58.07 (23.85)

 

59.48 (27.05)

 

52.76 (29.82)

 

60.71 (25.95)

 

61.96 (20.66)

 

Household monthly income per capita (Yuan)

  

16.37***a

 

7.30**

 

1.18

 

2.57

 

9.98***

< 600 I

34

46.81 (22.34)

 

52.94 (23.64)

 

47.18 (26.59)

 

52.12 (21.80)

 

51.68 (24.17)

 

600 ~ 6000 II

349

62.74 (24.78)

 

64.25 (26.37)

 

53.98 (28.42)

 

59.11 (27.35)

 

61.27 (22.07)

 

> 6000 III

100

71.06 (20.36)

 

71.83 (25.05)

 

55.71 (27.27)

 

63.72 (26.34)

 

69.67 (20.81)

 

post-hoc

 

I<II<III b

 

I<III, II<III c

 

NS c

 

NS c

 

I<III, II<III c

 

Plasma HIV-1 RNA level (copies/ml)

  

0.02

 

0.14

 

0.27

 

2.91

 

< 0.01

< 20

189

58.50 (24.57)

 

59.45 (24.90)

 

54.12 (24.75)

 

55.35 (26.39)

 

57.43 (22.74)

 

≥ 20

23

57.49 (30.55)

 

57.39 (26.95)

 

51.27 (24.21)

 

65.22 (24.34)

 

57.66 (21.90)

 

CD4+T cell count (cell/µl)

  

14.86*** a

 

8.20***

 

5.03** a

 

3.91*

 

20.07*** a

< 200 I

77

49.75 (28.77)

 

57.97 (25.50)

 

44.10 (30.40)

 

53.61 (28.99)

 

48.92 (25.23)

 

200 ~ 500 II

238

63.67 (23.83)

 

63.28 (25.65)

 

56.32 (25.87)

 

59.20 (26.57)

 

62.42 (21.51)

 

> 500 III

112

70.01 (19.14)

 

72.29 (24.06)

 

54.54 (27.88)

 

64.48 (24.28)

 

69.88 (18.06)

 

post-hoc

 

I<II<III b

 

I<III, II<III c

 

I<II, I<III b

 

I<III c

 

I<II<III b

 

HIV serostatus

  

3.02 a

 

0.11

 

3.59* a

 

0.29

 

5.62** a

HIV positive-asymptomaticI

282

65.09 (22.21)

 

65.08 (26.20)

 

56.65 (26.18)

 

60.32 (25.84)

 

65.32 (19.04)

 

HIV positive-symptomaticII

85

64.90 (24.71)

 

65.96 (27.23)

 

52.01 (30.51)

 

59.02 (28.65)

 

59.10 (25.65)

 

AIDSIII

116

57.95 (28.32)

 

64.20 (25.90)

 

48.42 (29.98)

 

58.14 (28.18)

 

57.45 (26.04)

 

post-hoc

 

NS b

 

NS c

 

III<I b

 

NS c

 

III<I b

 

Comorbidity

  

8.64** a

 

2.23

 

1.29

 

1.1

 

3.46

No

337

65.69(21.99)

 

66.26(25.05)

 

54.81(27.19)

 

60.40(26.20)

 

63.69(20.57)

 

Yes

146

57.91(28.51)

 

62.17(28.75)

 

51.66(30.02)

 

57.65(28.40)

 

59.20(25.87)

 

Liver function

  

0.11

 

0.55

 

1.65

 

2.23

 

< 0.01

Normal

126

63.07(24.32)

 

67.25(25.42)

 

50.96(28.74)

 

56.57(25.73)

 

62.83(20.83)

 

Abnormal

334

63.90(24.34)

 

65.22(26.49)

 

54.74(28.00)

 

60.78(27.37)

 

62.88(22.79)

 

Kidney function

  

0.05

 

0.05

 

0.18

 

0.1

 

0.89

Normal

432

64.22(24.24)

 

66.24(26.13)

 

53.74(28.31)

 

59.61(27.08)

 

62.99(22.19)

 

Abnormal

16

62.85(20.76)

 

64.79(25.38)

 

56.77(28.78)

 

61.81(26.44)

 

68.30(18.70)

 

Dyslipidemia

  

12.61***

 

0.92

 

1.51

 

0.34

 

2.92

No

71

75.27(17.08)

 

73.99(25.87)

 

58.69(29.48)

 

63.61(27.10)

 

70.59(18.26)

 

Yes

264

66.41(23.64)

 

70.63(26.23)

 

53.93(28.76)

 

61.49(27.17)

 

65.95(20.85)

 
  1. NS: Not significant. Abnormal liver function: glutamic pyruvic transaminase (ALT) or glutamic oxaloacetic transaminase (AST) exceeds the reference range, or AST/ALT > 1. Abnormal kidney function: Serum creatinine or glomerular filtration rate (GFR) exceeds the reference range, or the GFR decline over 25%. Dyslipidemia: Total cholesterol ≥ 5.2 mmol/L, or triglyceride ≥ 1.7 mmol/L, or low-density lipoprotein ≥ 3.4 mmol/L, high-density lipoprotein < 1.0 mmol/L, and non-high-density lipoprotein ≥ 4.1 mmol/L
  2. a: Welch’s ANOVA was used
  3. b: Games-Howell test was conducted to make multiple comparisons
  4. c: Scheffe’s method was used to make multiple comparisons
  5. I, II, III: Number for subgroup of variables with more than two groups
  6. *p<0.05
  7. **p<0.01, ***p<0.001